Kash Patel Becomes the Focus of Media Analysis They Consistently Get Wrong
How America Has Destroyed Its Democracy, Part Two: The Aristocracy of Merit
Three Congressional Missteps on Healthcare
Today’s Qualifications to Be President of the U.S.
Climate Alarmists Howl After EPA Rescinds ‘Endangerment Finding’
Ukraine's Bureaucrats Are Finishing What China Started
Rising Federal Debt: Why Strategic Planning Matters More Than Ever for High-Net-Worth Fami...
Classroom Political Activism Shifts a Teacher’s Role from Educator to Indoctrinator
As America Celebrates 250, We Must Help Iran Celebrate Another 2,500
Guatemalan Citizen Admits Using Stolen Identity to Obtain Custody of Teen Migrant
Oregon-Based Utility PacifiCorp Settles for $575M Over Six Devastating Wildfires
Armed Man Rammed Substation Near Las Vegas in Apparent Terror Plot Before Committing...
DOJ Moves to Strip U.S. Citizenship From Former North Miami Mayor Over Immigration...
DOJ Probes Three Michigan School Districts That Allegedly Teach Gender Ideology
5th Circuit Vacates Ruling That Blocked Louisiana's Mandate to Display 10 Commandments in...
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
West Virginia on the Right Track to Lower Drug Costs, But is it Enough?
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Related:

DRUGS HEALTH CARE

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement